Oncopeptides AB (publ) (LON:0RN4)

Market Cap	47.77M +90.2%
Revenue (ttm)	5.73M +124.7%
Net Income	-20.12M
EPS	-0.09
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	68,960
Open	n/a
Previous Close	1.545
Day's Range	n/a
52-Week Range	1.452 - 6.505
Beta	-1.83
RSI	25.00
Earnings Date	Feb 19, 2026

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hyd...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 75
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RN4

Financial Performance

In 2025, Oncopeptides AB's revenue was 71.12 million, an increase of 124.72% compared to the previous year's 31.65 million. Losses were -249.59 million, -12.31% less than in 2024.

Financial numbers in SEK